The RIME inhibitor also increased the proportion of CD8+ T cells and cytotoxic CD8+ T cells in ESCC patient‐derived xenografts (Figure 5I), suggesting that RIME is a promising therapeutic target. Here, CD8A is linked to esophageal squamous cell carcinoma.